Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as C$1.41 and last traded at C$1.42, with a volume of 64429 shares trading hands. The stock had previously closed at C$1.52.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The stock’s 50 day moving average price is C$1.77 and its two-hundred day moving average price is C$2.18. The firm has a market capitalization of C$117.83 million, a price-to-earnings ratio of -2.79 and a beta of 0.70.

Insiders Place Their Bets

In related news, Senior Officer Guillermo Torre acquired 17,240 shares of the stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of C$1.81 per share, for a total transaction of C$31,277.77. Company insiders own 4.57% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.